[go: up one dir, main page]

AU2001254672A1 - Farnesyl protein transferase inhibitor combinations with an her2 antibody - Google Patents

Farnesyl protein transferase inhibitor combinations with an her2 antibody

Info

Publication number
AU2001254672A1
AU2001254672A1 AU2001254672A AU5467201A AU2001254672A1 AU 2001254672 A1 AU2001254672 A1 AU 2001254672A1 AU 2001254672 A AU2001254672 A AU 2001254672A AU 5467201 A AU5467201 A AU 5467201A AU 2001254672 A1 AU2001254672 A1 AU 2001254672A1
Authority
AU
Australia
Prior art keywords
her2 antibody
protein transferase
transferase inhibitor
farnesyl protein
inhibitor combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001254672A
Inventor
Christopher J. Bowden
Ivan David Horak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2001254672A1 publication Critical patent/AU2001254672A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001254672A 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with an her2 antibody Abandoned AU2001254672A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00200692 2000-02-29
EP00200692 2000-02-29
PCT/EP2001/002163 WO2001064246A2 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with an her2 antibody

Publications (1)

Publication Number Publication Date
AU2001254672A1 true AU2001254672A1 (en) 2001-09-12

Family

ID=8171111

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001254672A Abandoned AU2001254672A1 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with an her2 antibody

Country Status (6)

Country Link
US (1) US20030022918A1 (en)
EP (1) EP1267929A2 (en)
JP (1) JP2003525252A (en)
AU (1) AU2001254672A1 (en)
CA (1) CA2397349A1 (en)
WO (1) WO2001064246A2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080038458A (en) 2000-05-19 2008-05-06 제넨테크, 인크. Genetic detection assays to improve the likelihood of an effective response to cancer therapy with ERW antagonists
US6794447B1 (en) * 2000-07-28 2004-09-21 Taylor Made Golf Co., Inc. Golf balls incorporating nanocomposite materials
WO2002028409A2 (en) * 2000-10-05 2002-04-11 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
AU2002360278A1 (en) * 2001-10-12 2003-11-11 Coley Pharmaceutical Gmbh Methods and products for enhancing immune responses using imidazoquinoline compounds
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
CA2547518A1 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089502A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089496A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089504A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
GT200500317A (en) 2004-11-05 2006-10-27 PROCESS TO PREPARE QUINOLINE COMPOUNDS AND PRODUCTS OBTAINED FROM THEM
PL1846030T3 (en) 2005-01-21 2019-05-31 Genentech Inc Fixed dosing of her antibodies
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
EP3195879A1 (en) * 2005-02-23 2017-07-26 Genentech, Inc. Extending time to disease progression or survival in cancer patients
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc HERCEPTIN® adjuvant therapy
AR054849A1 (en) 2005-07-26 2007-07-18 Wyeth Corp DIAZEPINOQUINOLINAS, SYNTHESIS OF THE SAME, AND INTERMEDIARIES TO OBTAIN THEM
EP2545919A1 (en) 2005-12-23 2013-01-16 Link Medicine Corporation Treatment of synucleinopathies
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2592156B1 (en) 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
JP2012508768A (en) * 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション Azaquinolinone derivatives and uses thereof
AR075896A1 (en) 2009-03-20 2011-05-04 Genentech Inc ANTI-HER ANTIBODIES (EPIDERMAL GROWTH FACTOR)
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
US8450090B2 (en) 2009-10-06 2013-05-28 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for promoting fatty acid production in plants
CA2784211C (en) 2010-02-18 2019-12-24 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN103890007A (en) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 Neuregulin antibodies and uses thereof
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
WO2013081645A2 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
JP2015514710A (en) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Diagnosis and treatment of HER3 inhibitors
HK1213250A1 (en) 2012-10-16 2016-06-30 Janssen Pharmaceutica, N.V. Heteroaryl linked quinolinyl modulators of roryt
PE20151203A1 (en) 2012-10-16 2015-08-31 Janssen Pharmaceutica Nv ROR-GAMMA-t PHENYL-LINKED QUINOLINYL MODULATORS
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
AU2014334619A1 (en) 2013-10-15 2016-04-21 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORyt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
EA000710B1 (en) * 1995-12-08 2000-02-28 Жансен Фармасетика Н.В. Farnesyl protein transerase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
JP4308919B2 (en) * 1997-04-25 2009-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Farnesyltransferase-inhibiting quinazolinones
AU4562799A (en) * 1998-06-15 2000-01-05 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ES2200591T3 (en) * 1998-12-23 2004-03-01 Janssen Pharmaceutica N.V. ANALYZED 1,2-QUINOLINE DERIVATIVES.

Also Published As

Publication number Publication date
CA2397349A1 (en) 2001-09-07
US20030022918A1 (en) 2003-01-30
WO2001064246A3 (en) 2002-02-21
EP1267929A2 (en) 2003-01-02
WO2001064246A2 (en) 2001-09-07
JP2003525252A (en) 2003-08-26

Similar Documents

Publication Publication Date Title
AU2001254672A1 (en) Farnesyl protein transferase inhibitor combinations with an her2 antibody
AU2001246477A1 (en) Farnesyl protein transferase inhibitor combinations with platinum compounds
AU2001240658A1 (en) Farnesyl protein transferase inhibitor combinations with camptothecin compounds
AU2001249865A1 (en) Pyrazoles for inhibiting protein kinase
AU2002210918A1 (en) Degraded agonist antibody
AU2001234125A1 (en) Antibody library
AU2001276737A1 (en) Protein injection preparations
AU2001247882A1 (en) Tricyclic protein kinase inhibitors
AU2001252147A1 (en) Farnesyl protein transferase inhibitor combinations
AU2001244166A1 (en) Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
AU2001246478A1 (en) Farnesyl protein transferase inhibitor combinations with taxane compounds
AU2001239275A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
AU2001234893A1 (en) Protein mapping
AU2001256166A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
AU2001253197A1 (en) Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
AU2001246934A1 (en) Agonist antibodies
AU2576501A (en) Protein kinase inhibitors
AU2001244167A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
AU2001272651A1 (en) Valves
AU2001242434A1 (en) Farnesyl protein transferase inhibitor combinations with vinca alkaloids
AU2001238522A1 (en) Market engine having optimization
AU2001273208A1 (en) Proteins associated with aging
MXPA03004878A (en) 0ovel farnesyl protein transferase inhibitors.
AU4431601A (en) Protein kinase assay
AU2001244863A1 (en) Apoptin-associating protein